Vivek Ramaswamy, JPM20 (Credit: Jeff Rumans)

Vivek Ra­maswamy's LNP de­liv­ery tech play Genevant scores $600M li­cens­ing deal from Take­da for nu­cle­ic acid ther­a­pies

With mR­NA vac­cines in high de­mand and new RNA ther­a­peu­tics crowd­ing on­to the mar­ket, the de­mand for lipid nanopar­ti­cles has nev­er been high­er. Now, one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.